High response rates for stage 1-II indolent B-cell lymphoma with yttrium-90 ibritumomab tiuxetan (Zevalin)

被引：0
|
作者：
Samaniego, F. [1 ]
Pro, B. [1 ]
Nunez, R. [1 ]
McLaughlin, P. [1 ]
Fanale, M. [1 ]
Kwak, L. [1 ]
Romaguera, J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [1] Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)
    Morschhauser, F
    Huglo, D
    Martinelli, G
    Paganelli, G
    Zinzani, P
    Hadjiyiannakis, D
    Liberati, A
    Illidge, T
    Milpied, N
    Kalmus, J
    Morel, P
    Reimann, U
    Marcus, R
    ANNALS OF ONCOLOGY, 2005, 16 : 54 - 54
  • [2] Experience with the use of yttrium-90 ibritumomab tiuxetan (Zevalin) in relapsed follicular lymphoma
    Demeter, J.
    Balassa, K.
    Domotor, M.
    Egyed, M.
    Gasztonyi, Z.
    Aryab, H.
    Gurzo, M.
    Ivayi, J.
    Klucsik, Zs.
    Sreter, L.
    Nagy, Zs.
    BLOOD REVIEWS, 2007, 21 : S138 - S139
  • [3] TREATMENT WITH YTTRIUM-90 (90Y)-IBRITUMOMAB TIUXETAN (ZEVALIN®) IN DIFFUSE LARGE B-CELL LYMPHOMA: A META-ANALYSIS
    Auger, S.
    Duny, Y.
    Daures, J. P.
    Quittet, P.
    HAEMATOLOGICA, 2014, 99 : 700 - 700
  • [4] Yttrium-90 (Ytracis) Labelled Ibritumomab Tiuxetan (Zevalin) in Patients with Relapsed or Refractory B-Cell non-Hodkin's Lymphoma
    Lipp, R. W.
    Piswanger-Soelkner, J. C.
    Dorda, A. F.
    Brezinschek, R. I.
    Lackner, H.
    Linkesch, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S93 - S93
  • [5] Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma
    Shah, Jatin
    Wang, Wenquan
    Harrough, V. Douglas
    Saville, Wayne
    Meredith, Ruby
    Shen, Sui
    Mueh, John
    Li, John
    Jasthy, Sri
    Maggass, Gregory
    Mckay, Charles
    Krumdieck, Richard
    Tharp, Morgan
    Winter, Christine
    Gregory, Stephanie
    Buchholz, William
    Awasthi, Sanjay
    Jacobs, Samuel
    Chung, Harold
    Egner, James
    Lobuglio, Albert F.
    Forero, Andres
    LEUKEMIA & LYMPHOMA, 2007, 48 (09) : 1736 - 1744
  • [6] Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin®) induces high response rates and durable remissions in patients with relapsed or refractory B-cell non hodgkin's lymphoma (NHL)
    Murray, JL
    Witzig, TE
    Molina, A
    Gordon, L
    Emmanouilides, C
    Vo, K
    Flinn, IW
    Czuczman, M
    Saville, W
    Wiseman, G
    White, CA
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S48 - S49
  • [7] Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results
    Steinhoff, M.
    Gellrich, S.
    Maza, S.
    Assaf, C.
    Orawa, H.
    Munz, D. L.
    Sterry, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] INTERIM ANALYSIS OF POST MARKETING SURVEILLANCE OF YTTRIUM-90 IBRITUMOMAB TIUXETAN IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA
    Hatake, K.
    Kanzaki, R.
    Yabuuchi, Y.
    Kataoka, O.
    Nagai, S.
    Asaeda, Y.
    HAEMATOLOGICA, 2016, 101 : 273 - 273
  • [9] A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
    Zinzani, P. L.
    Tani, M.
    Fanti, S.
    Stefoni, V.
    Musuraca, G.
    Castellucci, P.
    Marchi, E.
    Farsad, M.
    Fina, M.
    Pellegrini, C.
    Alinari, L.
    Derenzini, E.
    de Vivo, A.
    Bacci, F.
    Pileri, S.
    Baccarani, M.
    ANNALS OF ONCOLOGY, 2008, 19 (04) : 769 - 773
  • [10] Yttrium-90 Ibritumomab Tiuxetan as a Single Agent in Patients With Pretreated B-Cell Lymphoma: Evaluation of the Long-Term Outcome
    Zinzani, Pier Luigi
    Gandolfi, Letizia
    Stefoni, Vittorio
    Fanti, Stefano
    Fina, Mariapaola
    Pellegrini, Cinzia
    Montini, Gian Carlo
    Derenzini, Enrico
    Broccoli, Alessandro
    Argnani, Lisa
    Pileri, Stefano
    Baccarani, Michele
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (04): : 258 - 261
12345